Skip to content

NMN: evidenze, dosaggio, sicurezza e interazioni

VOTO BPromettente

β-Nicotinamide mononucleotide

Reviewed by CureMed LabsAggiornato il Ogni studio citato di seguito è un trial randomizzato condotto sull'uomo
In parole semplici

This is a supplement your body can turn into a molecule your cells need for energy and repair, which naturally drops as you age. It has decent early evidence in people, but scientists still don't know if raising this molecule actually makes you healthier long-term.

In sintesi
What it is
A direct NAD+ precursor. NAD+ declines with age and drives cellular energy and repair.
Evidence
Raises blood NAD+; improved walking distance, muscle insulin sensitivity, and cholesterol in separate trials. No lifespan or disease-outcome data.
Studied dose
250–2,000 mg/day orally, over 4 to 10 weeks.
Safety
No safety issues reported in published trials at up to 2,000 mg/day. Nothing is known beyond 10 weeks.
In conclusione
Reasonable to try if you understand you are buying biomarker and short-term functional evidence, not proven life extension — and only after checking it against the medications you already take.
Evidenze

Cosa mostrano davvero gli studi sull'uomo

Solo trial randomizzati e controllati con placebo condotti sull'uomo. I dati sugli animali non compaiono mai in questa sezione: non possono innalzare una valutazione e vengono indicati separatamente più sotto.

  1. 01
    Science2021Muscle insulin sensitivity
    Disegno
    Randomized, double-blind, placebo-controlled
    Dose
    250 mg/day
    Durata
    10 weeks

    25 postmenopausal women with prediabetes who were overweight or obese

    Insulin-stimulated glucose disposal in muscle rose 25±7% versus no change on placebo. Notably, muscle NAD+ content itself did not change, and body composition, blood pressure, lipids, and grip strength were unaffected. No adverse events were reported.

    doi:10.1126/science.abe9985
  2. 02
    GeroScience2022Dose-ranging, NAD+ and physical function
    Disegno
    Randomized, multicentre, double-blind, placebo-controlled
    Dose
    300, 600 or 900 mg/day
    Durata
    60 days

    80 healthy middle-aged adults

    Blood NAD+ rose at every dose. Six-minute walking distance improved versus placebo at all three doses, and self-reported health scores improved. The authors reported efficacy highest at 600 mg/day. No safety issues were found at any dose.

    doi:10.1007/s11357-022-00705-1
  3. 03
    Journal of Clinical Endocrinology & Metabolism2023Cardiometabolic markers
    Disegno
    Randomized, placebo-controlled (2:1)
    Dose
    1,000 mg twice daily (a pharmaceutical-grade NMN, MIB-626)
    Durata
    28 days

    30 overweight or obese adults aged 45 and over

    Body weight fell 1.9 kg, LDL cholesterol 18.7 mg/dL, and diastolic blood pressure 7.0 mmHg versus placebo. Insulin sensitivity, intra-abdominal fat, muscle strength and aerobic capacity did not change. Adverse events were similar between groups.

    doi:10.1210/clinem/dgad027
  4. 04
    Journal of the International Society of Sports Nutrition2021Aerobic capacity, alongside training
    Disegno
    Randomized, double-blind, placebo-controlled
    Dose
    300, 600 or 1,200 mg/day
    Durata
    6 weeks

    48 amateur runners in structured training

    Oxygen uptake and both ventilatory thresholds improved at 600 and 1,200 mg/day versus placebo. Peak power and VO₂max did not change — and every participant was training 5–6 times a week, so this is not an effect of NMN alone.

    doi:10.1186/s12970-021-00442-4
Cosa manca

No human trial has measured lifespan, disease outcomes, or anything beyond 10 weeks of dosing. The trials also disagree with each other: NMN improved muscle insulin sensitivity in the Science trial but changed nothing about insulin sensitivity in the JCEM trial. And in the one study that looked, muscle NAD+ content did not rise even though blood NAD+ did — so the mechanism people assume is at work has not actually been shown in muscle.

Grade B promettente. Multiple randomized human trials show real biomarker and functional effects, but no trial has measured disease outcomes or run longer than 10 weeks. Come valutiamo le evidenze.

Sicurezza

Effetti collaterali e sicurezza

Reported in trials
Mild nausea, flushing and gastrointestinal discomfort. Published randomized trials reported NMN as well tolerated, with adverse events similar to placebo.
Serious events
None attributed to NMN in the published randomized trials to date.
The honest caveat
The longest published trial ran 10 weeks. Long-term safety — the thing that actually matters for a compound you would take for decades — is unknown.
Interazioni

Interazioni con i farmaci

La sezione che la maggior parte dei siti sulla longevità omette. Se assumete farmaci da prescrizione, leggete questa parte prima di qualsiasi altra cosa in questa pagina.

Diabetes medication (metformin, insulin, GLP-1 agonists)

NMN improved muscle insulin sensitivity in one randomized trial. A combined effect on glucose control is plausible, so check your readings more closely in the first weeks.

Da monitorare
Blood-pressure medication

Diastolic blood pressure fell 7 mmHg in one trial. Additive lowering is plausible — recheck home readings during the first week.

Da monitorare
Lipid-lowering medication (statins, ezetimibe)

LDL cholesterol fell in one trial. Not a safety problem, but it can confound how you read your next lipid panel — tell whoever ordered it.

Nota
Active cancer treatment

NAD+ biology cuts both ways in oncology and the human data does not settle it. Do not add NMN during treatment without your oncologist's explicit sign-off.

Attenzione
Pregnancy and breastfeeding

No trials have been conducted in pregnancy or breastfeeding. Absence of data is not evidence of safety — avoid.

Attenzione
Stato legale

NMN è legale nel luogo in cui vivi?

Lo stato normativo viene monitorato per singolo mercato e verificato alla data indicata. Quando un composto non è autorizzato, questo sito non rimanda a venditori.

United States

Widely sold as a dietary supplement. The FDA moved to exclude NMN from that category in 2022 on drug-preclusion grounds, and the position remains unresolved — products stay on sale while it is contested.

Fonte: US Food and Drug Administration

Disponibile · controverso
United Kingdom

Treated as an unauthorised novel food. It is not legally sold as a food supplement in the UK, and no NMN product has completed novel-food authorisation.

Fonte: UK Food Standards Agency

Non autorizzato
European Union

Same novel-food position as the UK: NMN has no authorisation for sale as a food supplement in the EU.

Fonte: European Commission / EFSA

Non autorizzato
France

La France applique le règlement européen sur les nouveaux aliments : le NMN n'est pas autorisé à la vente comme complément alimentaire.

Fonte: European Commission / EFSA

Non autorizzato
Spain

España aplica el reglamento europeo de nuevos alimentos: el NMN no está autorizado para su venta como complemento alimenticio.

Fonte: European Commission / EFSA

Non autorizzato
Germany

Germany applies the EU novel-food rules, so NMN may not be sold as a food supplement. Products reaching German buyers are imported against that position.

Fonte: BVL / European Commission

Non autorizzato
United Arab Emirates

Sold openly as an anti-aging dietary supplement through MOHAP/DHA-licensed pharmacy chains (Life Pharmacy, BinSina Pharmacy, Al Ain Pharmacy, Aster) and mainstream UAE retailers such as noon.com. We found no public record of MOHAP applying the drug-precedence dispute the US FDA has raised, or of any specific import restriction on NMN — but we also could not query MOHAP's own product-registration database directly, so this reflects observed retail availability through licensed channels rather than a published MOHAP policy statement on NMN specifically.

Fonte: UAE Ministry of Health and Prevention (MOHAP)

Disponibile
Saudi Arabia

Sold as an anti-aging dietary supplement by Saudi retailers including Dr. Nutrition KSA. As with the UAE, we could not query SFDA's own product-registration database directly, so this reflects observed retail availability rather than a published SFDA policy statement on NMN specifically.

Fonte: Saudi Food and Drug Authority (SFDA)

Disponibile
Italyil tuo

L'Unione Europea non ha ancora autorizzato l'NMN come nuovo alimento (novel food) ai sensi del regolamento (UE) 2015/2283, quindi la vendita come integratore alimentare non è legale in nessuno Stato membro, Italia inclusa. Nonostante ciò, diversi prodotti a base di NMN risultano notificati nel Registro nazionale degli integratori alimentari del Ministero della Salute — una notifica è un'autodichiarazione dell'azienda, verificata solo a posteriori, e non equivale a un giudizio di conformità al regolamento sui novel food. Segnaliamo questo scarto reale tra la norma europea e la prassi di mercato italiana piuttosto che ignorarlo.

Fonte: Commissione europea / EFSA; Ministero della Salute (registro nazionale, non equivale ad autorizzazione novel food)

Non autorizzato
Netherlands

De Europese Commissie bepaalde in 2022 dat NMN een niet-toegelaten nieuw voedingsmiddel (novel food) is; er loopt inmiddels een EFSA-veiligheidsbeoordeling, maar nog geen goedkeuring. Anders dan in Italië lijkt Nederland dit ook daadwerkelijk te handhaven: de brancheorganisaties IVG en NPN meldden dat de verkoop van NMN-producten niet is toegestaan en dat aanbieders producten van de markt hebben moeten halen. We citeren deze brancheberichten omdat we geen directe NVWA-publicatie over een specifieke handhavingsactie konden vinden.

Fonte: Europese Commissie / EFSA; NVWA (via brancheorganisaties IVG/NPN)

Non autorizzato
Brazil

A Anvisa havia proibido o NMN em alimentos pela Resolução-RE nº 1.139/2022. Essa proibição foi revogada pela Resolução-RE nº 3.245, publicada em 14 de agosto de 2026, com base na Instrução Normativa nº 418/2025, que passou a autorizar o NMN em suplementos alimentares como fonte de niacina (vitamina B3) — com um teto de aproximadamente 94,85 mg de NMN por dia e advertência obrigatória no rótulo informando que o produto não deve ser consumido por gestantes, lactantes e crianças. É uma mudança muito recente; ainda não observamos como o mercado brasileiro está se ajustando a ela.

Fonte: Agência Nacional de Vigilância Sanitária (ANVISA)

Disponibile
Dosaggio

Dosaggio e tempistica

Studied range
250–2,000 mg/day

600 mg was where efficacy peaked in the only dose-ranging trial. Higher doses have been tested for safety, not for extra benefit.

Timing
Morning, with food

Matches how the trials dosed it. No published evidence favours evening dosing.

Form
Capsules are fine

Every positive human trial used ordinary oral dosing. No head-to-head study shows sublingual or liposomal forms beat plain capsules.

Costo: A dose inside the studied range costs meaningfully more than the low-dose products that dominate the shelf — the Science trial noted that typical commercial capsules contain 50–150 mg, well under what the trials used.

Domande

Le domande che le persone fanno davvero

Is NMN safe for long-term daily use?

Unknown, and that is the honest answer. Trials of up to 10 weeks at doses up to 2,000 mg/day reported no safety issues, but nobody has published multi-year human safety data. For a compound people intend to take for decades, that is a real gap rather than a formality.

What dose of NMN is most effective?

In the only trial that compared doses head to head, blood NAD+ and physical performance responded best at 600 mg/day, with 900 mg offering no clear additional benefit. Doses above that have been tested for safety, not for extra effect.

Does NMN or NR raise NAD+ better?

Both raise NAD+ in humans and no head-to-head trial has crowned a winner. NR has longer-running safety data; NMN has the stronger functional-outcome trials so far. Worth knowing: several randomized trials of NR in middle-aged and older men found no effect on insulin sensitivity, which is where NMN showed its clearest result.

Do sublingual or liposomal NMN products absorb better?

That claim runs ahead of the evidence — every positive human trial used ordinary oral capsules or powder. Choose on third-party testing and price per effective dose rather than on a delivery-format story.

Will NMN make me live longer?

No study has shown that in humans. NMN extends healthspan measures in mice, but the human trials have measured biomarkers and short-term function only. Anyone telling you otherwise is describing rodent data.

Recensioni

Recensioni su NMN

Ancora nessuna recensione — sii il primo.
Scrivi una recensione

Ogni recensione viene letta dal nostro team prima della pubblicazione. Non rimuoviamo nulla perché negativo — solo perché falso, fuori tema o offensivo.